Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France

References

• Reichert JM. Antibodies to watch in 2016. mAbs 2016; 8:197-204; PMID:26651519; http://dx.doi.org/10.1080/19420862.2015.1125583
   PubMed Web of Science ®Google Scholar
• Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, Hao W, Zhu Q, Bernard K, Zhu J, et al. An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLoS Pathog 2013; 9:e1003520; PMID:23935498; http://dx.doi.org/10.1371/journal.ppat.1003520
   PubMed Web of Science ®Google Scholar
• Turner RB, Wecker MT, Pohl G, Witek TJ, McNally E, St George R, Winther B, Hayden FG. Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA 1999; 281:1797-804; PMID:10340366; http://dx.doi.org/10.1001/jama.281.19.1797
   PubMed Web of Science ®Google Scholar
• Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N, Mori M, Pham T-H, Ward CK, Criner GJ, et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015; 42:566-79; PMID:25786179; http://dx.doi.org/10.1016/j.immuni.2015.02.011
   PubMed Web of Science ®Google Scholar
• Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, Rees DG, Overed-Sayer CL, Woods J, Bond NJ, et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Commun 2015; 6:8327; PMID:26365875; http://dx.doi.org/10.1038/ncomms9327
   PubMed Web of Science ®Google Scholar
• Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, Hoiby N, Fas SC, Lang AB. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob Agents Chemother 2010; 54:2338-44; PMID:20308370; http://dx.doi.org/10.1128/AAC.01142-09
   PubMed Web of Science ®Google Scholar
• Secher T, Fauconnier L, Szade A, Rutschi O, Fas SC, Ryffel B, Rudolf MP. Anti-Pseudomonas aeruginosa serotype O11 LPS immunoglobulin M monoclonal antibody panobacumab (KBPA101) confers protection in a murine model of acute lung infection. J Antimicrob Chemother 2011; 66:1100-9; PMID:21393169; http://dx.doi.org/10.1093/jac/dkr038
   PubMed Web of Science ®Google Scholar
• Secher T, Fas S, Fauconnier L, Mathieu M, Rutschi O, Ryffel B, Rudolf M. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PloS One 2013; 8:e73396; PMID:24023870; http://dx.doi.org/10.1371/journal.pone.0073396
   PubMed Web of Science ®Google Scholar
• Que Y-A, Lazar H, Wolff M, François B, Laterre P-F, Mercier E, Garbino J, Pagani J-L, Revelly J-P, Mus E, et al. Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol 2014; 33:1861-7; http://dx.doi.org/10.1007/s10096-014-2156-1
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-50; PMID:17167137; http://dx.doi.org/10.1056/NEJMoa061884
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol Off J Am Soc Clin Oncol 2009; 27:1227-34; http://dx.doi.org/10.1200/JCO.2007.14.5466
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet Lond Engl 2014; 384:665-73; http://dx.doi.org/10.1016/S0140-6736(14)60845-X
   PubMed Web of Science ®Google Scholar
• Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015; 16:763-74; PMID:26045340; http://dx.doi.org/10.1016/S1470-2045(15)00021-2
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G, Szczesna A, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015; 16:328-37; PMID:25701171; http://dx.doi.org/10.1016/S1470-2045(15)70046-X
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crin∫ L, Eberhardt WEE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, Molina J, Kim J-H, Arvis CD, Ahn M-J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet Lond Engl 2016; 387:1540-50; http://dx.doi.org/10.1016/S0140-6736(15)01281-7
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372:2018-28; PMID:25891174; http://dx.doi.org/10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet Lond Engl 2016 Apr 30;387(10030):1837-46.
   Google Scholar
• Verdoliva A, Bellofiore P, Rivieccio V, Catello S, Colombo M, Albertoni C, Rosi A, Leoni B, Anastasi AM, De Santis R. Biochemical and biological characterization of a new oxidized avidin with enhanced tissue binding properties. J Biol Chem 2010; 285:9090-9; PMID:20100839; http://dx.doi.org/10.1074/jbc.M109.080457
   PubMed Web of Science ®Google Scholar
• De Santis R, Rosi A, Anastasi AM, Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D, Carollo V, Marra E, et al. Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab. Oncotarget 2014; 5:9239-55; PMID:25238453; http://dx.doi.org/10.18632/oncotarget.2409
   PubMed Web of Science ®Google Scholar
• Bruchard M, Rebé C, Derangère V, Togbé D, Ryffel B, Boidot R, Humblin E, Hamman A, Chalmin F, Berger H, et al. Corrigendum: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol 2015; 16:1292; PMID:26580508; http://dx.doi.org/10.1038/ni1215-1292a
   PubMed Web of Science ®Google Scholar
• Besnard A-G, Togbe D, Couillin I, Tan Z, Zheng SG, Erard F, Le Bert M, Quesniaux V, Ryffel B. Inflammasome-IL-1-Th17 response in allergic lung inflammation. J Mol Cell Biol 2012; 4:3-10; PMID:22147847; http://dx.doi.org/10.1093/jmcb/mjr042
   PubMed Web of Science ®Google Scholar
• Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P, Ledru A, Apetoh L, Ghiringhelli F, Chamaillard M, et al. Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J Mol Cell Biol 2015; 7:351-65; PMID:25714839; http://dx.doi.org/10.1093/jmcb/mjv012
   PubMed Web of Science ®Google Scholar
• Lamas B, Richard ML, Leducq V, Pham H-P, Michel M-L, Da Costa G, Bridonneau C, Jegou S, Hoffmann TW, Natividad JM, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 2016; 22(6):598-605; PMID:27158904; http://dx.doi.org/10.1038/nm.4102
   PubMed Web of Science ®Google Scholar
• Michaudel C, Couturier-Maillard A, Chenuet P, Maillet I, Mura C, Couillin I, Gombault A, Quesniaux VF, Huaux F, Ryffel B. Inflammasome, IL-1 and inflammation in ozone-induced lung injury. Am J Clin Exp Immunol 2016; 5:33-40; PMID:27168953
   PubMed Web of Science ®Google Scholar
• Roversi P, Ryffel B, Togbe D, Maillet I, Teixeira M, Ahmat N, Paesen GC, Lissina O, Boland W, Ploss K, et al. Bifunctional lipocalin ameliorates murine immune complex-induced acute lung injury. J Biol Chem 2013; 288:18789-802; PMID:23625922; http://dx.doi.org/10.1074/jbc.M112.420331
   PubMed Web of Science ®Google Scholar
• Koussoroplis SJ, Paulissen G, Tyteca D, Goldansaz H, Todoroff J, Barilly C, Uyttenhove C, Van Snick J, Cataldo D, Vanbever R. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J Control Release Off J Control Release Soc 2014; 187:91-100; http://dx.doi.org/10.1016/j.jconrel.2014.05.021
   PubMed Web of Science ®Google Scholar
• Goebeler M-E, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma 2016; 57:1021-32; PMID:27050240; http://dx.doi.org/10.3109/10428194.2016.1161185
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. mAbs 2016; 1-12; PMID:26984268; http://dx.doi.org/10.1080/19420862.2016.1162932
   PubMed Web of Science ®Google Scholar
• Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med Off Publ Soc Nucl Med 2013; 54:1869-75; http://dx.doi.org/10.2967/jnumed.112.118612
   PubMed Web of Science ®Google Scholar
• Dijkers ECF, Kosterink JGW, Rademaker AP, Perk LR, van Dongen GAMS, Bart J, de Jong JR, de Vries EGE, Lub-de Hooge MN. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med Off Publ Soc Nucl Med 2009; 50:974-81; http://dx.doi.org/10.2967/jnumed.108.060392
   PubMed Web of Science ®Google Scholar
• Fick RB Jr, Fox JA, Jardieu PM. Immunopharmacology. 2000 Jul 25; 48(3):307-10. Review; http://dx.doi.org/10.1016/S0162-3109(00)00229-0
   Google Scholar
• Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, Ruppel J, Su JQ, Adelman DC. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160:1023-7; PMID:10471635; http://dx.doi.org/10.1164/ajrccm.160.3.9810012
   PubMed Web of Science ®Google Scholar
• Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Hervé V, Montharu J, Guillon A, Andres CR, Hérault O, Le Pape A, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Control Release 2014 Dec 28;196:344-54; PMID:25451545
   PubMed Web of Science ®Google Scholar
• Lightwood D, O'Dowd V, Carrington B, Veverka V, Carr MD, Tservistas M, Henry AJ, Smith B, Tyson K, Lamour S, et al. The discovery, engineering and characterisation of a highly potent anti-human IL-13 fab fragment designed for administration by inhalation. J Mol Biol 2013; 425:577-93; PMID:23219467; http://dx.doi.org/10.1016/j.jmb.2012.11.036
   PubMed Web of Science ®Google Scholar
• Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother 2016; 60:6-13; http://dx.doi.org/10.1128/AAC.01802-15
   PubMed Web of Science ®Google Scholar
• Murphy KM, Travers P, Walport M. Janeway's Immunobiology. Seven edition. New York: Garland Science; 2007.
   Google Scholar
• Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012; 11:958-72; PMID:23197041; http://dx.doi.org/10.1038/nrd3792
   PubMed Web of Science ®Google Scholar
• Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331-7; PMID:19352366; http://dx.doi.org/10.1038/nbt0409-331
   PubMed Web of Science ®Google Scholar
• Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, et al. Aerodynamical, immunological and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharm Res 2008; 25:1318-26; PMID:18030605; http://dx.doi.org/10.1007/s11095-007-9481-3
   PubMed Web of Science ®Google Scholar
• Respaud R, Marchand D, Parent C, Pelat T, Thullier P, Tournamille J-F, Viaud-Massuard M-C, Diot P, Si-Tahar M, Vecellio L, et al. Effect of formulation on the stability and aerosol performance of a nebulized antibody. mAbs 2014; 6:1347-55; PMID:25517319; http://dx.doi.org/10.4161/mabs.29938
   PubMed Web of Science ®Google Scholar
• Hervé V, Rabbe N, Guilleminault L, Paul F, Schlick L, Azzopardi N, Duruisseaux M, Fouquenet D, Montharu J, Redini F, et al. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. mAbs 2014; 6:1638-48; http://dx.doi.org/10.4161/mabs.34454
   PubMed Web of Science ®Google Scholar
• Laucho-Contreras ME, Taylor KL, Mahadeva R, Boukedes SS, Owen CA. Automated measurement of pulmonary emphysema and small airway remodeling in cigarette smoke-exposed mice; Am J Respir Crit Care Med. 2000 Jun;161(6):1957-62; PMID:25651034; http://dx.doi.org/10.3791/52236
   PubMedGoogle Scholar
• Lee J-H, Lee D-S, Kim E-K, Choe K-H, Oh Y-M, Shim T-S, Kim S-E, Lee Y-S, Lee S-D. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 2005; 172:987-93; PMID:16002570; http://dx.doi.org/10.1164/rccm.200501-041OC
   PubMed Web of Science ®Google Scholar
• Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005; 172:848-53; PMID:15961691; http://dx.doi.org/10.1164/rccm.200411-1549OC
   PubMed Web of Science ®Google Scholar
• Polverino F, Doyle-Eisele M, McDonald J, Wilder JA, Royer C, Laucho-Contreras M, Kelly EM, Divo M, Pinto-Plata V, Mauderly J, et al. A novel nonhuman primate model of cigarette smoke-induced airway disease. Am J Pathol 2015; 185:741-55; PMID:25542772; http://dx.doi.org/10.1016/j.ajpath.2014.11.006
   PubMed Web of Science ®Google Scholar
• Laucho-Contreras ME, Polverino F, Gupta K, Taylor KL, Kelly E, Pinto-Plata V, Divo M, Ashfaq N, Petersen H, Stripp B, et al. Protective role for club cell secretory protein-16 (CC16) in the development of COPD. Eur Respir J 2015; 45:1544-56; PMID:25700379; http://dx.doi.org/10.1183/09031936.00134214
   PubMed Web of Science ®Google Scholar
• Lundgren R, Söderberg M, Hörstedt P, Stenling R. Morphological studies of bronchial mucosal biopsies from asthmatics before and after ten years of treatment with inhaled steroids. Eur Respir J 1988; 1:883-9; PMID:3224689
   PubMed Web of Science ®Google Scholar
• Spina D, Page CP. Asthma – a need for a rethink?. Trends Pharmacol Sci 2002; 23:311-5; PMID:12119151; http://dx.doi.org/10.1016/S0165-6147(02)02022-9
   PubMed Web of Science ®Google Scholar
• Van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J 2000; 16:514-33; PMID:11028670; http://dx.doi.org/10.1034/j.1399-3003.2000.016003514.x
   PubMed Web of Science ®Google Scholar
• Keir SD, Spina D, Douglas G, Herd C, Page CP. Airway responsiveness in an allergic rabbit model. J Pharmacol Toxicol Methods 2011; 64:187-95; PMID:21854860; http://dx.doi.org/10.1016/j.vascn.2011.08.003
   PubMed Web of Science ®Google Scholar
• Minshall EM, Riccio MM, Herd CM, Douglas GJ, Seeds EA, McKenniff MG, Sasaki M, Spina D, Page CP. A novel animal model for investigating persistent airway hyperresponsiveness. J Pharmacol Toxicol Methods 1993; 30:177-88; PMID:8123899; http://dx.doi.org/10.1016/1056-8719(93)90015-7
   PubMed Web of Science ®Google Scholar
• Keir S, Page C, Spina D. Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves. J Allergy Clin Immunol 2002; 110:388-94; PMID:12209084; http://dx.doi.org/10.1067/mai.2002.126661
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther 2006; 318:840-8; PMID:16682455; http://dx.doi.org/10.1124/jpet.105.099192
   PubMed Web of Science ®Google Scholar
• Franciosi LG, Diamant Z, Banner KH, Zuiker R, Morelli N, Kamerling IMC, de Kam ML, Burggraaf J, Cohen AF, Cazzola M, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 2013; 1:714-27; PMID:24429275; http://dx.doi.org/10.1016/S2213-2600(13)70187-5
   PubMed Web of Science ®Google Scholar
• Grandin C, Lucas-Hourani M, Clavel M, Taborik F, Vabret A, Tangy F, Contamin H, Vidalain P-O. Evidence for an intranasal immune response to human respiratory syncytial virus infection in cynomolgus macaques. J Gen Virol 2015; 96:782-92; PMID:25537374; http://dx.doi.org/10.1099/vir.0.000039
   PubMed Web of Science ®Google Scholar
• Grandin C, Hourani M-L, Janin YL, Dauzonne D, Munier-Lehmann H, Paturet A, Taborik F, Vabret A, Contamin H, Tangy F, et al. Respiratory syncytial virus infection in macaques is not suppressed by intranasal sprays of pyrimidine biosynthesis inhibitors. Antiviral Res 2016; 125:58-62; PMID:26593978; http://dx.doi.org/10.1016/j.antiviral.2015.11.006
   PubMed Web of Science ®Google Scholar
• Zeitlinger M, Müller M, Joukhadar C. Lung microdialysis–a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J 2005; 7:E600-608; PMID:16353939; http://dx.doi.org/10.1208/aapsj070362
   PubMed Web of Science ®Google Scholar
• de la Peña A, Liu P, Derendorf H. Microdialysis in peripheral tissues. Adv Drug Deliv Rev 2000; 45:189-216; http://dx.doi.org/10.1016/S0169-409X(00)00106-X
   PubMed Web of Science ®Google Scholar